Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy (oHCM) in Japan
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:
• • All obstructive hypertrophic cardiomyopathy (oHCM) patients who initiate treatment with Mavacamten of the approved indications at medical institutions in Japan during enrollment period will be enrolled in this regulatory post-marketing surveillance (PMS) study
Locations
Other Locations
Japan
CMIC Co., Ltd
RECRUITING
Tokyo
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2025-05-21
Estimated Completion Date: 2029-11-30
Participants
Target number of participants: 200
Treatments
Cohort 1
Participants with obstructive hypertrophic cardiomyopathy receiving mavacamten treatment
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb